ESCORT-NEO
Regimen
- Experimental
- neoadjuvant camrelizumab + nab-paclitaxel/cisplatin (Cam+nab-TP); or camrelizumab + paclitaxel/cisplatin (Cam+TP); both with adjuvant camrelizumab
- Control
- neoadjuvant paclitaxel/cisplatin (TP)
Population
Resectable thoracic locally advanced ESCC (T1b-3N1-3M0 or T3N0M0)
Key finding
pCR 28.0% (Cam+nab-TP) vs 15.4% (Cam+TP) vs 4.7% (TP); both IO arms significantly superior. EFS immature. G3+ TRAE 34.1%/29.2%/28.8%.
Source: PMID 38956195